Adenomyosis: Can IVF in Thailand Be an Option? Indications & Process Explained
Opening: Real Consultation Scenario
📋 Real Consultation Scenario
A 34-year-old patient with adenomyosis walked into the clinic carrying three domestic ovarian stimulation protocols and a CA125 report. She had previously attempted two intrauterine inseminations (IUI) in her home country, both unsuccessful. Ultrasound showed heterogeneous echogenicity in the posterior myometrium, with a lesion measuring approximately 3.8cm × 2.6cm, and CA125 levels fluctuating between 85–120 U/ml. She asked, "Given my condition, can IVF in Thailand work for me? Is changing location the solution?"
This is a very typical question and a common source of confusion for many women with adenomyosis considering overseas IVF. Below, I will break down this issue from a practical reproductive medicine perspective.
Module A: Direct Answer
I. Direct Answer: Yes, but Specific Conditions Must Be Met
Patients with adenomyosis can undergo IVF in Thailand, but "can" does not mean "suitable for everyone." From a medical standpoint, achieving a favorable outcome with IVF in Thailand depends on three core variables: lesion type and severity, ovarian reserve, and uterine environment status.
✅ Suitable for IVF:
- Diffuse adenomyosis without significant uterine enlargement (uterine cavity morphology is essentially normal);
- Focal adenomyosis (adenomyoma) where the lesion does not compress the endometrium;
- Normal ovarian reserve (AMH ≥1.2 ng/ml, antral follicle count AFC ≥6);
- Lesion size reduced and CA125 normalized or near-normal after GnRH-a down-regulation.
❌ Conditions where directly starting a cycle is not recommended:
- Uterine volume larger than 10 weeks of pregnancy (severely deformed uterine cavity);
- Coexisting bilateral endometriomas with significantly diminished ovarian function;
- Previous multiple IVF transfer failures with ultrasound indicating poor endometrial receptivity;
- Persistently high CA125 >200 U/ml with unsatisfactory response to standard down-regulation.
Simply put: IVF in Thailand cannot change adenomyosis itself, but it can improve the chance of embryo implantation through medication pretreatment, optimized stimulation protocols, and embryo selection. It is not a "cure" for adenomyosis, but a pathway to pursue pregnancy under the existing lesion conditions.
Module C: Doctor's PerspectiveII. Doctor's Perspective: Core Impact of Adenomyosis on IVF
In reproductive medicine, adenomyosis is believed to potentially affect IVF outcomes through several mechanisms:
- Altered uterine environment: Lesions cause reduced subendometrial blood flow and elevated local inflammatory factors, potentially lowering embryo implantation rates;
- Abnormal uterine cavity morphology: Severe adenomyosis can elongate and deform the uterine cavity, affecting embryo localization and implantation;
- Interference with ovarian stimulation response: Some studies suggest patients with adenomyosis may have decreased sensitivity to FSH, requiring higher stimulation doses;
- Increased miscarriage risk: The local inflammatory environment in the uterus after pregnancy may increase the probability of early miscarriage.
However, these effects vary greatly among individuals. Clinically, it is common to see: among patients with the same diffuse adenomyosis, some succeed with a single transfer while others experience repeated failure. The difference often lies in lesion activity (CA125 level and fluctuation trend) and myometrial compliance. Therefore, the key to success with IVF in Thailand is not the act of "going to Thailand," but thorough lesion assessment and pretreatment before starting the cycle.
Module D: Age-Based Strategy DifferencesIII. Strategy Differences by Age Group
| Age Group | Core Focus | Pretreatment Emphasis | IVF Strategy in Thailand |
|---|---|---|---|
| ≤35 years | Good ovarian reserve, lesion management is key | 2–3 cycles of GnRH-a down-regulation; monitor CA125 and uterine volume | Consider fresh embryo transfer or freeze-all followed by elective endometrial preparation |
| 36–40 years | Balance ovarian function and uterine environment | Assess AMH, AFC during down-regulation; shorten down-regulation cycle if necessary | Prefer frozen embryo transfer, prioritize lesion control before transfer |
| ＞40 years | Declining ovarian reserve is the main issue | Proceed quickly with cycle, avoid prolonged down-regulation; utilize embryo PGT screening | Accumulate embryos, then transfer during the optimal window for endometrial receptivity |
Age is a critical variable independent of adenomyosis. For patients over 40, the rate of egg quality decline often outpaces the benefits of lesion management, so treatment strategies need to be more time-sensitive.
Module G: Most Overlooked DetailsIV. Most Overlooked Details
In daily consultations, I find the following details are often overlooked by patients but have a substantial impact on outcomes:
- CA125 fluctuation trend is more important than a single value: A single normal CA125 does not mean the lesion is inactive; continuous monitoring over 3 months to see the trend is more meaningful;
- Standard for measuring uterine volume: Don't just look at "uterine size normal" on the ultrasound report; pay attention to uterine cavity length and whether the endometrial line is clear;
- Longer down-regulation is not always better: 2–3 months is the common window; exceeding 4 months may over-suppress the ovaries, affecting subsequent stimulation;
- Timing of embryo transfer: Patients with adenomyosis are more suitable for transfer in a hormone replacement therapy (HRT) cycle, as it allows more flexible control of endometrial preparation time;
- Graded management of adenomyosis in Thai hospitals: Experience with adenomyosis pretreatment varies significantly between hospitals; it is necessary to confirm the laboratory and doctor's relevant experience in advance.
V. Common Pitfalls
Pitfall 1: Believing "IVF success rates are higher in Thailand" and thus ignoring lesion pretreatment. In reality, without down-regulation before starting the cycle, the implantation rate for adenomyosis patients might be even lower than domestically—because stress from long flights and environmental changes can exacerbate inflammation.
Pitfall 2: Blindly choosing PGT without evaluating uterine issues. PGT can only screen for chromosomally normal embryos; it cannot solve uterine receptivity problems. Many adenomyosis patients fail not because of poor embryo quality, but because the uterus "does not accept" it.
Pitfall 3: Ignoring male factors. Adenomyosis patients tend to focus all attention on themselves, but male semen quality and DNA fragmentation rate also affect the final outcome.
Pitfall 4: Overly trusting "sex selection with IVF in Thailand" while ignoring medical indications. Sex selection is legally restricted in Thailand and has no connection with adenomyosis treatment.
VI. Actual Process: Key Steps from Evaluation to Transfer
A standard IVF process in Thailand for adenomyosis patients typically includes the following stages:
- Domestic Pre-Evaluation (1–2 weeks): Complete 3D ultrasound of the uterus, CA125, AMH, AFC, semen analysis, infectious disease screening, and karyotype testing. Some hospitals require hysteroscopy to rule out endometrial polyps or adhesions.
- Telemedicine Consultation (1 week): Submit reports to the Thai fertility center for the doctor to evaluate the pretreatment plan. Usually, 2–3 cycles of GnRH-a down-regulation are recommended first.
- Pretreatment Before Departure (2–3 months): Complete down-regulation injections either domestically or in Thailand, once every 28 days. Monitor CA125 and uterine volume changes during this period.
- Ovarian Stimulation in Thailand (approx. 12–14 days): Start stimulation on day 2–3 of menstruation upon arrival in Thailand. Typically use an antagonist protocol or long protocol, adjusting dosage based on individual response.
- Egg Retrieval and Embryo Culture (1 week): Perform ICSI after retrieval, culture to blastocyst stage. Whether to do PGT depends on embryo quality and patient preference.
- Frozen Embryo Transfer Cycle (1–2 months): It is recommended to freeze all embryos after retrieval and perform elective transfer once the lesion is stable. Prepare the endometrium using an HRT protocol, starting luteal phase support 5–7 days before transfer.
- Post-Transfer Management (12–14 days): Check blood HCG on day 12 post-transfer. If pregnancy is confirmed, continue luteal phase support until 10–12 weeks of gestation.
| Stage | Time Required | Key Actions |
|---|---|---|
| Domestic Pre-Evaluation | 1–2 weeks | 3D uterine ultrasound, CA125, AMH, semen analysis |
| Down-regulation Pretreatment | 2–3 months | GnRH-a injections every 28 days, monitor CA125 |
| Ovarian Stimulation Cycle | 12–14 days | Antagonist/long protocol, adjust based on follicular response |
| Embryo Culture/Freezing | 1 week | Blastocyst culture, PGT optional |
| Frozen Embryo Transfer | 1–2 months | HRT endometrial preparation, elective transfer |
| Pregnancy Confirmation | 14 days | Blood HCG test, luteal phase support |
VII. Special Situation Management
The following clinical scenarios require individualized strategy adjustments:
- Coexisting Endometrioma: If the cyst diameter is >4 cm or accompanied by pain, it is recommended to perform ultrasound-guided aspiration or laparoscopic cystectomy before starting the IVF process. Direct stimulation may cause the cyst to enlarge or rupture.
- Previous Multiple Transfer Failures: Consider endometrial receptivity array (ERA) and chronic endometritis testing (CD138+). Some adenomyosis patients have concurrent chronic inflammation, and antibiotic treatment may improve outcomes.
- Adenomyosis with Fibroids: If the fibroid is submucosal or intramural and compresses the endometrium, hysteroscopic or laparoscopic management is recommended before considering IVF.
- Persistently Elevated CA125: Try extending down-regulation to 3–4 cycles, or switch to a GnRH-antagonist protocol combined with letrozole. A few patients may need to pause the IVF plan to control lesion progression first.
VIII. Frequently Asked Questions
Q1: Is the success rate of IVF in Thailand higher than domestically for adenomyosis?
Success rate does not depend on location, but on whether lesion management is thorough. Some hospitals in Thailand have more experience in adenomyosis pretreatment and blastocyst culture, but this is not absolute. Large domestic fertility centers also have mature adenomyosis management protocols. The key is to look for a hospital with a systematic adenomyosis pretreatment pathway, not simply "going to Thailand."
Q2: Can I work and live normally during down-regulation?
Yes. After GnRH-a injection, low estrogen symptoms (hot flashes, joint pain, mood swings) may occur, but most people can live normally. It is recommended to supplement calcium and vitamin D appropriately and avoid strenuous exercise.
Q3: What special tests are required for adenomyosis patients in Thailand?
In addition to routine ovarian function assessment, Thai hospitals generally require CA125 trend over the past 3 months, 3D ultrasound of the uterus (to assess depth and extent of myometrial infiltration), and some centers may recommend saline infusion sonography or hysteroscopy to rule out endometrial pathology.
Q4: Do I need to stay in bed after the transfer?
No. Live normally after transfer, avoiding prolonged standing and heavy physical labor. Prolonged bed rest may actually affect pelvic blood circulation, which is unfavorable for adenomyosis patients.
IX. Risk Reminder and Doctor's Advice
⚠️ Important Risk Reminder:
- Patients with adenomyosis have an increased risk of miscarriage, preterm birth, pregnancy-induced hypertension, and placental abnormalities compared to the general population. Closer antenatal monitoring is required during pregnancy.
- IVF in Thailand cannot reduce obstetric complications related to adenomyosis. Post-pregnancy, high-risk pregnancy management is still needed in a tertiary hospital in your home country.
- Some patients may experience prolonged low estrogen status after down-regulation, increasing the risk of decreased bone density. Calcium supplementation and monitoring of bone metabolism markers are recommended.
👨⚕️ Reproductive Specialist's Advice:
Before considering IVF in Thailand, patients with adenomyosis should complete at least 3 months of lesion stability assessment. Do not rush into a cycle, and do not give up easily after one failure. Clinically, I have seen many adenomyosis patients achieve favorable pregnancy outcomes after thorough pretreatment. The key is: Prioritize lesion management; IVF technology is just a tool, not the answer.
If you are struggling with the decision "should I go to Thailand," first complete these three things: ① Monitor CA125 continuously for three months; ② Get a 3D ultrasound of the uterus to assess lesion extent; ③ Check AMH and AFC. Once these three results are available, the direction will be clear.
This article covers: Adenomyosis IVF success rate in Thailand · Adenomyosis IVF protocol in Thailand · CA125 and IVF decision-making · Adenomyosis down-regulation pretreatment · Precautions for adenomyosis IVF in Thailand · Advanced age adenomyosis overseas IVF · Adenomyosis with endometrioma IVF strategy
